Fig 1.

Pseudomonadota relative abundances in participants who received MET-2 (n = 13) or FMT (n = 5). Pseudomonadota are summarized at the species level in the baseline (A) and 1 month post-intervention stool samples (B). (A and B) Species contributing <1% relative abundance in at least one sample were aggregated as “Others.” Species contributing <5% relative abundance but ≥1% in at least one sample are in gray. (C) Pseudomonadota relative abundance between baseline and 1 month post-intervention. (D) Enterobacteriaceae relative abundance between baseline and 1 month post-intervention. (E) 16S rRNA DNA density (ng/μL) between baseline and 1 month post-intervention. (F) γ-Proteobacteria DNA density (ng/μL) between baseline and 1 month post-intervention. (C–F) Values are log-transformed, where dots represent individual participants with lines connecting the same participants measured at different time points. Participant 10 and Participant 3 are highlighted as individuals who failed initial MET-2 or FMT therapy, respectively. Medians are plotted with P-values displayed above the MET-2 interventional group. Pairwise analysis performed using Wilcoxon matched-pairs signed-rank test.